Clinical Trial

Comparative Effects Of Post Isometric Relaxation Versus Active Isolated Stretch In Patients With Piriformis Syndrome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the comparative effects of post-isometric relaxation (PIR) and active isolated stretch (AIS) techniques on reducing pain, improving range of motion, and decreasing functional disability in individuals with piriformis syndrome. A total of 40 participants will be recruited, aged 20-55 yrs, with confirmed piriformis syndrome. Participants will be randomized into two equal groups. Group A (post isometric relaxation) and Group B (active isolated stretch). Both groups will receive Conventional Therapy (Thermotherapy, Electrotherapy). Study variables include: * Independent Variable: Post Isometric Relaxation and Active Isolated Stretching. * Dependent Variables: Pain (measured by Visual Analog Scale), Functional Disability (assessed via Oswestry Disability Index), Range of Motion (assessed via Goniometer). * Control Variables: Age, Gender, BMI, Baseline Pain/ Disability Scores/ROM The intervention will last 2 weeks with 6 sessions (3 sessions per week). Assessments will be conducted at baseline (Week 1, Pre-treatment) and Post every second session. Data will be analyzed to compare immediate and short-term effects of the two interventions. This study aims to provide evidence for targeted manual therapy approaches in priformis syndrome, potentially guiding clinicians toward the most effective technique for pain reduction, improve ROM and decrease functional disability.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-06.
Trial Details
NCT Number NCT07526012
Lead Sponsor Foundation University Islamabad
Conditions Piriformis Syndrome, Low Back Pain, Hip Joint
Enrollment 40 participants
Start Date 2026-05-20
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-20